Followers | 37 |
Posts | 4190 |
Boards Moderated | 0 |
Alias Born | 10/18/2016 |
Thursday, July 13, 2017 2:08:50 PM
- In the U.S., more than 5.3 million people suffer from Alzheimer’s disease, and 46 million around the world have it
- Alzheimer’s disease cost the U.S. more than $236 billion in 2016, and the global costs topped $600 billion
- In 2017, IGC acquired exclusive rights to an Alzheimer’s treatment, based on THC, from the University of South Florida
- Huge valuation growth potential in light of other Alzheimer’s and cannabis-based companies
India Globalization Capital, Inc. (NYSE MKT: IGC) has been working on phytocannabinoid-based therapies for various medical conditions for some time. Its drug development pipeline consists of treatments for seizures, neuropathic pain, and eating disorders, but one gaining attention is an experimental cannabis-based drug for Alzheimer’s disease, IGC-AD1. A University of South Florida patent was issued in July 2015. However, the study of using cannabis to treat the disease began long before that. A Molecular Pharmaceutics report (http://nnw.fm/kF241) suggested that cannabinoids could be useful in treating patients, back in 2008; that was long before a scientific study made a breakthrough in 2014, claiming tetrahydrocannabinol (THC) had the potential to be a therapeutic agent for Alzheimer’s in a published report released by the Journal of Alzheimer’s Disease.
In a recent Benzinga article (http://nnw.fm/Xnq88), the details of the study were highlighted. Scientists suggested that THC molecules, representing one of marijuana’s main chemical compounds, could bind to and break up amyloid-beta protein, which is associated with plaques that form around nerve cells. The effectiveness has not overruled any concerns regarding safety. Clinical trials, though, have found the side effects of THC to be mostly tolerable for patients, and proper doses have been correlated with positive results. Many Alzheimer’s patients have experienced reduced delusions or mood problems.
In the elderly, the disease is a leading cause of dementia. The number of cases is expected to increase and even triple within 50 years, adding to the hardship on the quality of life of individuals and the associated health care costs. Treatment options have aimed at slowing or halting the progression. With THC, studies have identified molecular mechanisms associated with how cannabinoid molecules have a direct effect on amyloid plaques in the brain and how the disease progresses.
The first pharmaceutical company listed on the NYSE to develop cannabis-based therapies for Alzheimer’s, IGC remains the only publicly-traded cannabis pharmaceutical stock to address the disease. Nonetheless, other studies have revealed therapeutic promise in this area. Researchers at the University of Bonn and the Hebrew University of Jerusalem tried cannabis on old mice with decreases in memory. A long term, low-dose regiment of cannabis restored their memory performance to that of a two-month old mouse. The results were published in the journal Nature Medicine.
Also, genetic activity at the molecular level, and brain tissue, became more like that of younger animals. This included an increase in nerve cell links in the brain. The study preceded clinical trials on humans, which have since yielded promising results.
Finally, and perhaps even more important from an investment standpoint, is IGC’s potential for market valuation growth, given the company’s pipeline of Hyalolex for Alzheimer’s and other phytocannabinoid-based therapies. Other companies focused on Alzheimer’s, such as AVXL, AXON, ACIU, and BIIB, sport market valuations in the hundreds of millions or even billions of dollars, while other cannabis-focused companies, such as CRBP and ZYNE, are already in the hundreds of millions.
To learn more about India Globalization Capital, its drug development pipeline, and its pursuit of cannabis-based therapies for Alzheimer’s patients, go to www.IGCInc.us
Recent IGC News
- IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two • Business Wire • 04/16/2024 11:00:00 AM
- IGC Pharma Adds Advisor in Artificial Intelligence • Business Wire • 04/09/2024 01:00:00 PM
- IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock • Business Wire • 03/26/2024 07:00:00 PM
- IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation • Business Wire • 03/20/2024 03:00:00 PM
- IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024 • Business Wire • 03/20/2024 11:00:00 AM
- IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline • Business Wire • 03/12/2024 07:00:00 PM
- Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model • Business Wire • 02/28/2024 06:00:00 PM
- IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target • Business Wire • 02/23/2024 05:01:00 PM
- IGC Pharma Reports Third Quarter Fiscal 2024 Results • Business Wire • 02/17/2024 12:05:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:03:00 PM
- IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model • Business Wire • 02/01/2024 02:20:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/31/2024 09:04:23 PM
- IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s • Business Wire • 01/23/2024 02:20:00 PM
- IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial • Business Wire • 01/17/2024 02:20:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/09/2024 05:15:07 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/29/2023 09:54:29 PM
- Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s • Business Wire • 12/19/2023 02:20:00 PM
- IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024 • Business Wire • 12/13/2023 02:30:00 PM
- IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials • Business Wire • 12/06/2023 01:30:00 PM
- IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives • Business Wire • 11/21/2023 01:30:00 PM
- IGC Pharma Reports Second Quarter Fiscal 2024 Results • Business Wire • 11/13/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:15:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 09:21:48 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/27/2023 08:38:17 PM
- IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy • Business Wire • 10/19/2023 07:30:00 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM